# The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study

> **NCT02200172** · PHASE2 · COMPLETED · sponsor: **Bruyère Health Research Institute.** · enrollment: 60 (actual)

## Conditions studied

- Cancer

## Interventions

- **OTHER:** Melatonin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02200172
- **Lead sponsor:** Bruyère Health Research Institute.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02200172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02200172, "The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02200172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*